Category

Archives

PI3K

Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review

2 views | Feb 22 2021

Priyanka Singh et al. thought that the PI3K/Akt/mTOR signaling pathway in multiple cancers, might improve the therapeutic approaches towards TKI-resistant CML cells where the respective signaling pathway got upregulated. [Read the Full Post]

The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells

0 views | Feb 21 2021

Kamira Maharaj et al. suggested that the improved safety profile of umbralisib was due to its role as a dual PI3Kδ/CK1ε inhibitor that preserved Treg number and function. [Read the Full Post]

Preclinical evaluation and Phase 1b study of prexasertib, a CHK1 inhibitor, and samotolisib (LY3023414), a dual PI3K/mTOR inhibitor

11 views | Jan 27 2021

David S Hong et al found that Prexasertib+samotolisib showed antitumor activity in preclinical models and preliminary efficacy in heavily-pretreated patients. [Read the Full Post]

Inhibition of Phosphatidylinositol 3-Kinase γ by IPI-549 Attenuates Abdominal Aortic Aneurysm Formation in Mice

12 views | Jan 04 2021

Rui Liu et al. found that inhibition of PI3Kγ limited AAA formation. Targeting PI3Kγ prevented inflammatory cell infiltration through inhibition of AKT phosphorylation in AAA. [Read the Full Post]

Small molecule 2,3-DCPE induces S phase arrest by activating the ATM/ATR-Chk1-Cdc25A signaling pathway in DLD-1 colon cancer cells

36 views | Oct 29 2020

Bingjun Bai et al. suggested that 2,3-DCPE caused DNA damage in colon cancer cells and that 2,3-DCPE-induced S phase arrest was associated with the activation of the ATM/ATR-Chk1-Cdc25A pathway. [Read the Full Post]

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

35 views | Oct 22 2020

Fabian Lang et al.thought that combined inhibition of PI3K and mTOR inhibited a clinically meaningful driver pathway in a small subset of patients with ALL, with no benefit in patients with AML. [Read the Full Post]

HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer

33 views | Oct 20 2020

Peter Kok-Ting Wan et al. provided that BEZ, but not GSK, could abolish Nurr1-enhanced radioresistance, suggesting its potential value for radiosensitizing CSLCs in the clinical setting. [Read the Full Post]

The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis

34 views | Oct 10 2020

Yangjiong Xiao et al. concluded that GSK458 might serve as an attractive candidate to treat ovarian cancer. [Read the Full Post]

Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma

38 views | Oct 05 2020

Monique Bernard et al. suggested a broader application for this combination therapy that could be promptly translated to in vivo studies. [Read the Full Post]

Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling

34 views | Oct 05 2020

Dong-Shan Zhu et al. supported the rationale for using omipalisib as a therapeutic approach in ESCC patients. [Read the Full Post]